Indeed, some high-risk localized prostate cancer patients, initially negative for metastasis on conventional imaging, are now being reclassified as part of the metastatic patient cohort when PSMA PET/CT detects oligometastases. This evidence concerns the gene FOLH1 and prostate carcinoma.